A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects
- Resource Type
- Article
- Authors
- Xu, Zhongnan; Wang, Yanli; Liu, Zhengzhi; Zhang, Renjie; Zhou, Yannan; Yu, Jing; Lan, Jing; Liang, Wenzhong; Liu, Guangwen; Qu, Xinyao; Chen, Jiahui; Su, Zhengjie; Yu, Shuang; Cheng, Yang; Wang, Wanhua; Ren, Qing; Deng, Qiaohuan; Zhao, Yicheng; Yang, Haimiao
- Source
- In International Immunopharmacology August 2022 109
- Subject
- Language
- ISSN
- 1567-5769